title: Platelet antiaggregants in primary and secondary prevention of atherothrombotic events.
abstract: Atherothrombosis and its complications are currently the leading cause of worldwide mortality and its incidence is increasing . Platelets play an essential role in the pathogenesis of atherothrombotic events, justifying the use of antiplatelet agents in their prevention. Thus, it is essential to know the efficacy and safety profile of these drugs in primary and secondary prevention of atherothrombotic events. In this context, this review was performed with the aim of describing and summarizing the outcomes of the main trials involving the use of antiplatelet agents in the two levels of prevention, and evaluating the effectiveness and major adverse events related to therapy.
authors.affiliation: Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. marcosvfs02@yahoo.com.br
authors.forename: Marcos Vinícius Ferreira
authors.initials: MV
authors.lastname: Silva
authors.forename: Luci Maria SantAna
authors.initials: LM
authors.lastname: Dusse
authors.forename: Lauro Mello
authors.initials: LM
authors.lastname: Vieira
authors.forename: Maria das Graças
authors.initials: Md
authors.lastname: Carvalho
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy / Q000517:prevention & control; D003328:Coronary Thrombosis / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011322:Primary Prevention / Q000379:methods*; D055502:Secondary Prevention / Q000379:methods*
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin